Success Metrics

Clinical Success Rate
92.3%

Based on 12 completed trials

Completion Rate
92%(12/13)
Active Trials
0(0%)
Results Posted
8%(1 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_1
5
36%
Ph phase_2
7
50%
Ph phase_3
2
14%

Phase Distribution

5

Early Stage

7

Mid Stage

2

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
5(35.7%)
Phase 2Efficacy & side effects
7(50.0%)
Phase 3Large-scale testing
2(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

85.7%

12 of 14 finished

Non-Completion Rate

14.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(12)
Terminated(2)

Detailed Status

Completed12
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
92.3%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (35.7%)
Phase 27 (50.0%)
Phase 32 (14.3%)

Trials by Status

terminated17%
withdrawn17%
completed1286%

Recent Activity

0 active trials
Showing 5 of 14
completedphase_2

Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer

NCT00479817
completedphase_2

AMG 386 and Abiraterone for Advanced Prostate Cancer

NCT01553188
completedphase_1

A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function

NCT01331941
terminatedphase_3

TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

NCT01493505
completedphase_1

To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.

NCT00861419
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT00479817Phase 2

Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer

Completed
NCT01553188Phase 2

AMG 386 and Abiraterone for Advanced Prostate Cancer

Completed
NCT01331941Phase 1

A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function

Completed
NCT01493505Phase 3

TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Terminated
NCT00861419Phase 1

To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.

Completed
NCT01204749Phase 3

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Completed
NCT01666977Phase 1

Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer

Completed
NCT00872014Phase 2

A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer

Completed
NCT00467025Phase 2

AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib

Completed
NCT00511459Phase 2

Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients

Completed
NCT00752570Phase 2

A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma

Completed
NCT01992341Phase 1

AMG 386 Drug-Drug Interaction Study With Paclitaxel

Completed
NCT01907308Phase 2

Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma

Withdrawn
NCT00102830Phase 1

Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14